AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $2.58, $0.06 better than the analyst estimate of $2.52. Revenue for the quarter came in at $15.29 billion versus the consensus estimate of $14.9 billion.

GUIDANCE

AstraZeneca reconfirms total revenue and core EPS guidance for FY 2026 at CER, based on the average foreign exchange rates through 2025. Total revenue is expected to increase by a mid-to-high single-digit percentage vs. estimated growth of 7.56% Y/Y. Core EPS is expected to increase by a low double-digit percentage vs. estimated growth of 12.04% Y/Y. The core tax rate is expected to be between 18% and 22%.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.